In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model.

ABSTRACT: IgE monoclonal antibodies hold great potential for cancer therapy. Preclinical in vivo systems, particularly those in which the antibody recognizes the host species target antigen and binds to cognate Fc receptors, are often the closest approximation to human exposure and represent a key challenge for evaluating the safety of antibody-based therapies. We sought to develop an immunocompetent rat system to assess the safety of a rodent anti-tumor IgE, as a surrogate for the human therapeutic candidate. We generated a rat IgE against the human tumor-associated antigen chondroitin sulfate proteoglycan 4 (CSPG4) and cross-reactive for the rat antigen. We analyzed CSPG4 distribution in normal rat and human tissues and investigated the in vivo safety of the antibody by monitoring cl

SUBMITTER: Williams IP 

PROVIDER: S-EPMC6927758 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature